Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | GBA1 | P04062 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.36 |
| ▸ | PLAU | P00749 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
| ▸ | GLS | O94925 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 4/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4768617 | 0.94 | ADRA2A (0.39) | CYP11B1CYP11B2GBA1KDM4EALDH1A1 | |
| SCHEMBL5650 | 0.88 | GBA1 (0.42) | CYP11B1CYP11B2GBA1KDM4EALDH1A1 | |
| SCHEMBL10461384 | 0.80 | GBA1 (0.48) | GBA1KDM4EALDH1A1GRM2GLS | |
| SCHEMBL7424809 | 0.80 | GBA1 (0.40) | GBA1KDM4EALDH1A1ADRA2AADRA2B | |
| SCHEMBL506458 | 0.79 | — | — | |
| SCHEMBL2358386 | 0.78 | GBA1 (0.47) | GBA1KDM4EALDH1A1ADRA2AADRA2B | |
| SCHEMBL15270538 | 0.78 | TSHR (0.50) | KDM4EALDH1A1GLSRAB9ATSHR | |
| SCHEMBL20133367 | 0.78 | ESR1 (0.44) | CYP11B1CYP11B2ALDH1A1 | |
| SCHEMBL9082300 | 0.77 | KCNH2 (0.48) | GBA1KDM4EALDH1A1ADRA2ARAB9A | |
| SCHEMBL22748383 | 0.77 | KCNH2 (0.48) | GBA1KDM4EALDH1A1ADRA2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846669-B2 | Oxazolidinone derivative and medical composition containing same | LEGOCHEM BIOSCIENCES, INC. (KR) | 2014-09-30 | — | — | US | disclosed |
| EP-2760854-A1 | IMIDAZOLE DERIVATIVES AS CYP17 INHIBITORS FOR THE TREATMENT OF CANCER | Endo Pharmaceuticals Inc. (US) | 2014-08-06 | — | — | EP | disclosed |
| US-20140179691-A1 | NOVEL OXAZOLIDINONE DERIVATIVE AND MEDICAL COMPOSITION CONTAINING SAME | LEGOCHEM BIOSCIENCES, INC. (KR) | 2014-06-26 | — | — | US | disclosed |
| WO-2013049565-A1 | IMIDAZOLE DERIVATIVES AS CYP17 INHIBITORS FOR THE TREATMENT OF CANCER | ENDO PHARMACEUTICALS INC. (US) | 2013-04-04 | — | — | WO | disclosed |
| US-8183275-B2 | Substituted imidazoles as bombesin receptor subtype-3 modulators | MERCK SHARP & DOHME CORP. (US) | 2012-05-22 | — | — | US | disclosed |
| US-20100204236-A1 | Substituted imidazoles as bombesin receptor subtype-3 modulators | MERCK SHARP & DOHME CORP. | 2010-08-12 | — | — | US | disclosed |
| US-20100022515-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2010-01-28 | — | — | US | disclosed |
| US-7592358-B2 | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-22 | — | — | US | disclosed |
| EP-2083623-A1 | SUBSTITUTED IMIDAZOLES AS BOMBESIN RECEPTOR SUBTYPE-3 MODULATORS | Merck & Co., Inc. (US) | 2009-08-05 | — | — | EP | disclosed |
| EP-1020445-B1 | FUSED PYRIDINE DERIVATIVES | EISAI R&D MAN CO LTD (JP) | 2008-08-13 | — | — | EP | disclosed |
| US-20020013460-A1 | Condensed pyridine compound | EISAI CO., LTD | 2002-01-31 | — | — | US | disclosed |
| US-6340759-B1 | ANTISPASMODIC AGENTS | EISAI CO., LTD. (JP) | 2002-01-22 | — | — | US | disclosed |
| EP-1157007-A1 | PDE IV INHIBITING COMPOUNDS, COMPOSITIONS AND METHODS OF TREATMENT | MERCK FROSST CANADA INC. (CA) | 2001-11-28 | — | — | EP | disclosed |
| US-6150526-A | Piperidine derivative having renin inhibiting activity | HOFFMANN-LA ROCHE INC. (US) | 2000-11-21 | — | — | US | disclosed |
| WO-2000050402-A1 | PDE IV INHIBITING COMPOUNDS, COMPOSITIONS AND METHODS OF TREATMENT | MERCK FROSST CANADA & CO. (CA) | 2000-08-31 | — | — | WO | disclosed |
| EP-1020445-A1 | FUSED PYRIDINE DERIVATIVES | Eisai Co., Ltd. (JP) | 2000-07-19 | — | — | EP | disclosed |
| US-6051712-A | PREVENTION OF HIGH BLOOD PRESSURE AND CARDIAC INSUFFICIENCY, AS WELL AS GLAUCOMA, CARDIAC INFARCT, KIDNEY INSUFFICIENCY AND RESTENOSIS | HOFFMANN-LA ROCHE INC. (US) | 2000-04-18 | — | — | US | disclosed |
| EP-0863875-A1 | NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY | F. HOFFMANN-LA ROCHE AG (CH) | 1998-09-16 | — | — | EP | disclosed |
| WO-1997009311-A1 | NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY | F. HOFFMANN-LA ROCHE AG (CH) | 1997-03-13 | — | — | WO | disclosed |
| US-4937251-A | TREATING ASTHMA AND BRONCHITIS; ADRENERGIC STIMULANTS | GLAXO GROUP LIMITED (GB) | 1990-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204236-A1 | Substituted imidazoles as bombesin receptor subtype-3 modulators | BRS3, GPR119, GIPR | CYP11B1 1233/4885CYP11B2 1522/4885GBA1 3245/4885 |
| US-20100022515-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | GPR119, GCGR, GPR65 | CYP11B1 667/4885CYP11B2 824/4885GBA1 1199/4885 |
| US-20020013460-A1 | Condensed pyridine compound | MUSK, HTR1A, PAX3 | CYP11B1 559/4885CYP11B2 436/4885GBA1 4305/4885 |
| US-20140179691-A1 | NOVEL OXAZOLIDINONE DERIVATIVE AND MEDICAL COMPOSITION CONTAINING SAME | OXA1L, PAM, ABCC1 | CYP11B1 366/4885CYP11B2 637/4885GBA1 3238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.